OncoSil Medical Ltd (AU:OSL) has released an update.
OncoSil Medical Ltd has announced a pivotal development in its clinical strategy, with the successful treatment of the first UK patient using the OncoSil™ device as part of the expansive TRIPP-FXX clinical study. Aimed at evaluating the device’s safety and efficacy in conjunction with standard FOLFIRINOX chemotherapy for locally advanced pancreatic cancer, the study spans 16-18 sites across Europe and Australia. The procedure marks a significant milestone in the company’s mission to integrate its treatment device with mainstream chemotherapy regimes and bolsters its growth strategy within Western Europe and the UK.
For further insights into AU:OSL stock, check out TipRanks’ Stock Analysis page.
